Drug DevelopmentUpcoming catalysts include Investigational New Drug submissions for HWK-007 and HWK-016 by the end of 2025, with Phase 1 trial initiation expected shortly after.
Financial StabilityWhitehawk ended 2Q25 with $177.2M in cash, cash equivalents, and marketable securities, which should provide an operational runway into 2028.
Strategic PartnershipsThe company announced the decision to revamp its portfolio through the sale of its commercial product Fyarro for $100MM in conjunction with in-licensing of 3 next-generation ADCs from Wuxi Biologics and HANGZHOU DAC.